The success of specific inhibitors hinges on accurately identifying molecular targets that are essential for cancer cell survival but less critical for normal cells. This specificity reduces the risk of damaging healthy tissues and minimizes side effects. Techniques like next-generation sequencing and proteomics have revolutionized target identification by providing comprehensive insights into the molecular landscape of cancer.
